XSTO
SCOL
Market cap100kUSD
Jul 11, Last price
0.00SEK
1D
-39.71%
1Q
-63.39%
IPO
-99.95%
Name
Scandion Oncology A/S
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.76%
Rev. gr., 5y
%
Revenues
0k
Net income
-39m
L-48.89%
CFO
-28m
L-45.69%
Earnings
Aug 27, 2025
Profile
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 45,803 | 72,076 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (45,803) | (72,076) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 5,500 | (5,500) | ||||||
Tax Rate | ||||||||
NOPAT | (51,303) | (66,576) | ||||||
Net income | (39,204) -48.89% | (76,700) 48.34% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 20,206 | 53,545 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 66 | 499 | 776 | |||||
Long-term debt | 66 | 499 | 2,418 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | (1,000) | |||||||
Net debt | (12,553) | (25,522) | (74,411) | |||||
| Cash flow | ||||||||
Cash from operating activities | (27,520) | (50,668) | (69,443) | |||||
CAPEX | (414) | |||||||
Cash from investing activities | 175 | 288 | (389) | |||||
Cash from financing activities | 13,511 | (705) | 41,727 | |||||
FCF | 4,788 | (53,901) | (67,231) | |||||
| Balance | ||||||||
Cash | 12,685 | 26,520 | 77,605 | |||||
Long term investments | ||||||||
Excess cash | 12,685 | 26,520 | 77,605 | |||||
Stockholders' equity | (224,281) | (201,886) | (162,681) | |||||
Invested Capital | 232,615 | 233,507 | 234,604 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 40,707 | 42,928 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 445 | (44,834) | (71,194) | |||||
EV/EBITDA | ||||||||
Interest | 495 | |||||||
Interest/NOPBT | ||||||||